This EDRN CVC application is a new submission by the Vanderbilt-lngram Cancer Center and its affiliated institutions. Cancer is now the number one killer of Americans, and lung cancer is the number one cause of cancer death, causing the deaths of more people than breast, colon, and prostate cancers combined. This multidisciplinary effort of experts in biomarker research proposes to take to phase II and III validation a set of biomarkers developed at our and at other institutions to address specifically the clinical utility of molecular signatures in the assessment of the diagnosis of lung cancer and of the risk of developing lung cancer. We propose a three way approach. First we propose to put diagnostic candidate signatures to the test in carefully designed case-controls studies in existing samples prospectively collected under the same standard operating procedure. Second, we will test candidate biomarkers of lung cancer development in an observational study of selected very high risk individuals from the Nashville community performing repeated measurements of clinical, imaging (chest CT) variables as well as molecular biomarker signatures some of which obtained from bronchoscopic procedures. Our hypothesis is that increased level of the biomarkers is associated with lung cancer and that measurement of the biomarker over time is likely to provide us with an advantage over the epidemiological and imaging data to detect the disease early and therefore to diagnose patients earlier, leading to larger number of patient candidates for surgical and definitive intervention. Third, we will centralize an effort to collect and store pertinent clinical data and tissues (blood, urine, and the airways specimens) following the Office of Biorepositories and Biospecimen Research guidelines as permitted by the study design and research participant authorization. We will make these resources available to the community and to collaborators within and outside of the EDRN program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-3 (M1))
Program Officer
Krueger, Karl E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Ajona, Daniel; Okrój, Marcin; Pajares, María J et al. (2018) Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget 9:6346-6355
Li, Qian; Balagurunathan, Yoganand; Liu, Ying et al. (2018) Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Clin Lung Cancer 19:148-156.e3
Deppen, Stephen Andrew; Massion, Pierre P; Blume, Jeffrey et al. (2018) Accuracy of a novel histoplasmosis enzyme immunoassay to evaluate suspicious lung nodules. Cancer Epidemiol Biomarkers Prev :
Magarik, Meaghan A; Walker, Ronald C; Gilbert, Jill et al. (2018) Intracardiac Metastases Detected by 18F-FSPG PET/CT. Clin Nucl Med 43:28-30
Codreanu, Simona G; Hoeksema, Megan D; Slebos, Robbert J C et al. (2017) Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma. J Proteome Res 16:3266-3276
Li, Qian; Kim, Jongphil; Balagurunathan, Yoganand et al. (2017) Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys 44:4341-4349
Massion, Pierre P; Healey, Graham F; Peek, Laura J et al. (2017) Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol 12:578-584
Walker, Ronald; Deppen, Stephen; Smith, Gary et al. (2017) 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One 12:e0171301
Mazzone, Peter J; Sears, Catherine Rufatto; Arenberg, Doug A et al. (2017) Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med 196:e15-e29
Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449

Showing the most recent 10 out of 38 publications